LG Chem announces initiation of two phase 2 clinical trials in patients with defects in MC4R pathway causing severe obesity and hyperphagia. - LG Chem cont...
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause More than half of women ages 40 to 64 wor...
Phase 1 study for SB16, proposed biosimilar to Prolia, demonstrates pharmacokinetic (PK) bioequivalence between SB16, EU-sourced denosumab, and US-source...
IPF is a chronic, progressive fibrosing interstitial pneumonia and one of the most fatal interstitial pneumonias. The incidence of IPF is high, but due to ...
Combination arms to treat patients in first-line setting, providing valuable insights on future development potential for this patient population Phase ...
The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the results from an interi...
Hansa Biopharma, "Hansa", a pioneer in enzyme technology for rare immunological conditions, announced high-level results from NICE-01, the first-in-h...
-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, announced an extension ...
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the su...
The study will evaluate the safety, tolerability, and efficacy of SCI-210, in comparison to CBD monotherapy in treating ASD. Designed as a randomized, doub...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluatin...
The enliGHten trial enrolled 298 participants (mean age 10.3 years) from the Phase 3 heiGHt Trial of treatment-naïve pediatric GHD patients and the Ph...
Patents valid through 2038 Clinical topline results from Phase 2b ALS trial expected in H2 2023 Corresponding patents have b...
© 2025 Biopharma Boardroom. All Rights Reserved.
